Title
Association Between Chronic Kidney Disease-Mineral Bone Disease (CKD-MBD) and Cognition in Children: Chronic Kidney Disease in Children (CKiD) Study.

Permalink
https://escholarship.org/uc/item/8fc543ch

Journal
Kidney medicine, 2(4)

ISSN
2590-0595

Authors
Yokoyama, Jennifer S
Matsuda-Abedini, Mina
Denburg, Michelle R
et al.

Publication Date
2020-07-01

DOI
10.1016/j.xkme.2020.03.005

Peer reviewed
Rationale & Objective: Chronic kidney disease (CKD) in children is associated with cognitive dysfunction that affects school performance and quality of life. The relationship between CKD–mineral and bone disorder and cognitive function in children is unknown.

Study Design: Observational study.

Participants: 702 children enrolled in the Chronic Kidney Disease in Children (CKiD) Study.

Predictors: Plasma fibroblast growth factor 23 (FGF-23), parathyroid hormone (PTH), calcium, phosphorus, 25 hydroxyvitamin D (25(OH)D), and 1,25 dihydroxyvitamin D (1,25(OH)₂D).

Outcomes: Neurocognitive tests of intelligence, academic achievement, and executive functions.

Analytical Approach: Linear regression models to analyze the cross-sectional associations between log₂FGF-23, 25(OH)D, 1,25(OH)₂D, PTH, calcium, and phosphorus z scores did not associate with cognitive test scores. In fully adjusted analyses, log₂FGF-23 was associated with abnormal test scores for attention regulation (P < 0.05); specifically, Conners’ Continuous Performance Test II Errors of Omission (β = 2.3 [1.0, 3.6]), Variability (β = 1.4 [0.4, –2.4]), and Hit Reaction Time (β = 1.3 [0.2, 2.4]). Children in the highest FGF-23 tertile group had 7% and 9% greater cognitive risk for Hit Reaction Time and Errors of Omission compared with those in the lowest tertile, respectively. In fully adjusted analyses, higher FGF-23 tertile was associated with increased cognitive risk (P < 0.05) for Errors of Omission (β = 0.4 [0.1, 0.7]) and Hit Reaction Time (β = 0.4 [0.1, 0.7]).

Limitations: The study does not assess the cumulative effects of FGF-23 excess on cognitive function over time. Within-population stratified analyses were not performed due to limited sample size.

Conclusions: In children with CKD, higher plasma FGF-23 level is associated with lower performance in targeted tests of executive function, specifically attention regulation, independent of glomerular filtration rate.

Chronic kidney disease (CKD) in children is associated with higher morbidity and mortality than seen in the general pediatric population.¹-³ Despite advances in the care of children with CKD, such as improved nutrition, anemia management, avoidance of aluminum-based phosphate binders, adequate dialysis, and timely kidney transplantation, emerging studies show that children with CKD remain at risk for cognitive dysfunction, particularly in the areas of attention regulation and associated executive functions.⁴ Cognitive dysfunction can lead to poor school performance and lower quality of life. Lower performance has been reported in measures of academic achievement, such as numerical operations, compared with chronological age expectations.⁵,⁶ In prior studies of children from the Chronic Kidney Disease in Children (CKiD) cohort, median cognitive function was within the range of normal values; however, 21% to 40% of participants scored at least 1 standard deviation (SD) below the normative mean on measures of intelligence quotient (IQ), achievement, attention, and executive functions.⁵,⁶ Similarly, in adults who had childhood-onset CKD, verbal and nonverbal IQ were lower than in their unaffected peers, and educational attainment and employment rates were lower compared with those without CKD.⁶,⁷ In adult-onset CKD, the prevalence of severe cognitive dysfunction in patients receiving dialysis is higher than the prevalence of dementia reported in community-based populations.⁸ Collectively, these studies show that children and adults with CKD are at increased risk for neurocognitive deficits that in turn can negatively affect their educational performance, disease self-management, occupational outcomes, and health-related quality of life. However, there is a paucity of literature on risk factors that increase the likelihood of cognitive dysfunction in CKD.

Fibroblast growth factor 23 (FGF-23) is a bone-derived circulating hormone that is critical for maintaining phosphorus and vitamin D homeostasis and thereby skeletal mineralization.¹¹,¹² In CKD, plasma FGF-23 level increases early and is associated with disordered mineral metabolism,⁵,¹²,¹³ CKD progression,¹⁶,¹⁷ left ventricular hypertrophy,⁹,¹⁸ poor cardiovascular health, and mortality.¹⁹-²²
PLAIN-LANGUAGE SUMMARY
Cognitive impairment is a known complication of chronic kidney disease (CKD) in children. However, little is known about risk factors that might increase the likelihood of cognitive impairment in CKD. The present study provides the first large-scale evaluation of associations between biomarkers of bone and mineral metabolism and cognitive function in children with predialysis CKD. Higher plasma fibroblast growth factor 23 (FGF-23) concentrations were independently associated with poor performance on cognitive function tests, specifically measures of attention regulation. Our study is the first to provide evidence for an association between plasma FGF-23 level and complications involving the central nervous system in children with CKD.

In preclinical studies, FGF-23 was shown to directly regulate neural networks in the hippocampus, an important region for learning, memory, and attention regulation. In adults with CKD, associations between circulating FGF-23 levels and neurologic complications, particularly impaired cognitive function, were examined, but the findings are controversial. In children, FGF-23 protein is detected in the cerebrospinal fluid but no prior studies have examined the relationship between levels of FGF-23 or other biomarkers of bone and mineral metabolism and cognitive function in children with and without CKD.

In the present study, we address this gap in the pediatric literature by testing the hypothesis that higher plasma FGF-23 level is associated with poor performance on specific measures of cognitive function in children with CKD. We also examine associations between other biomarkers of bone and mineral metabolism and cognitive function in this population.

METHODS
The CKiD Study is a prospective observational study that enrolled 891 children aged 1 to 16 years with estimated glomerular filtration rates (eGFRs) between 30 and 90 mL/min/1.73 m² at 54 centers across North America from January 2005 to March 2015. The study design, methods, and exclusion criteria have been described previously. The study was approved by the UCSF Institutional Review Board #18-25119, and all participants provided informed consent.

Participants
For the present cross-sectional analysis, we included 702 children aged 6 to 16 years in whom baseline measurement of plasma FGF-23, mineral metabolism biomarkers, and neurocognitive testing were performed 3 to 6 months after enrollment.

Neurocognitive Tests
A battery of tests was carefully administered to assess key areas of cognitive functions (Table S1). All tests were standardized, age normed, age appropriate, and administered to each study participant by a trained psychologist or trained technician supervised by the psychologist at each site. We selected specific cognitive tests to: (1) align with literature pertaining to cognition in mild to moderate CKD and (2) have strong psychometric properties that included age-based normative data. These measures include the Wechsler Abbreviated Scales of Intelligence-2 (WASI-2; intellectual function); Wechsler Individual Achievement Test-II-Abbreviated (WIAT-II-A; Total Achievement [academic achievement]); Conners’ Continuous Performance Test-II (CPT-II; Errors of Omission, Errors of Commission, Hit Reaction Time, Detectability, and Variability [selective attention, impulsivity, and attention regulation]); Digit Span Backwards from the age-appropriate Wechsler Intelligence Scale (verbal working memory); parent ratings on the Behavior Rating Inventory of Executive Functions (BRIEF; executive functions) summary scores of Behavior Regulation Index (BRI), Metacognition Index, and Global Executive Composite.

Biochemistries
We measured plasma C-terminal FGF-23 using a second-generation enzyme-linked immunosorbent assay (Immunotopics Int); inter- and intra-assay coefficients of variation were 11.5% and 5.7%, respectively. Median plasma FGF-23 value in healthy children of comparable age was 57 (2.5th and 97.5th percentiles, 17 and 101) RU/mL. Serum vitamin D metabolites were measured using Heartland Assays as described. All other biochemistry test results were determined at the CKiD Central Biochemistry Laboratory, University of Rochester. Kidney function was determined by eGFR calculations using the full CKiD (eGFRCKiDfull) equation based on serum creatinine, cystatin C, and serum urea nitrogen levels; height; and sex. eGFR data were collected at all study visits compared with iohexol GFR, which was measured at select time points only. eGFRCKiDfull closely approximated measured iohexol GFR to describe relationships between risk factors and CKD progression in this pediatric population and is the preferred equation for research purposes using this pediatric cohort.

Statistical Analysis
All analyses presented are cross-sectional, using plasma FGF-23, serum 25-hydroxyvitamin D (25[OH]D), 1,25-dihydroxyvitamin D (1,25[OH]2D), parathyroid hormone (PTH), calcium, and phosphorus levels obtained at baseline as the primary exposure. Values were expressed...
either as a continuous or a categorical variable using tertiles. Values of FGF-23 were log2-transformed to satisfy normality assumptions. Values of phosphorus for each participant were expressed as a z score relative to age-matched values in healthy children.36

The primary outcome of interest was neurocognitive test performance; test values for each assessment were compared with age-appropriate norms from the general population and expressed as a standard score. Cognitive risk was defined as a standard score ≥ 1 SD below the test mean (categorical outcome). Higher cognitive test scores indicate better performance for WASI-2, WIAT-II-A, and Digit Span Backwards. Higher scores indicate worse performance for CPT-II tests, BRI, Metacognition Index, and Global Executive Composite.

We tested for differences in the distribution of each of the cognitive test standard scores across tertiles of plasma FGF-23 using the Kruskal-Wallis test and examined the unadjusted associations between cognitive test standard scores and log2 plasma FGF-23 (representing per doubling) using Pearson correlation. We also tested for differences in the prevalence of cognitive risk for each cognitive test across tertiles of FGF-23 using 2-tailed χ2 test and examined the associations between cognitive risk and log2 FGF-23 using 1-way analysis of variance. When 1 or more cognitive function tests was associated with either log2 FGF-23 or FGF-23 tertiles at a significance level < 0.1, we performed multivariable regression analyses as described next for all measures within the specific cognitive domain of interest.

We used linear regression models to examine the association between log2 FGF-23, 25(OH)D, 1,25(OH)2D, PTH, calcium, and phosphorus z score values and cognitive test score(s) of interest. Model 1 was unadjusted; model 2 was adjusted for sex, age, race, and Hispanic ethnicity (yes/no); model 3 was additionally adjusted for eGFR and urine protein-creatinine ratio (UPCR, yes/no ≥ 2); and model 4 was additionally adjusted for hypertension (defined as systolic blood pressure [BP] ≥ 95th percentile). In separate analyses, we used multivariable logistic regression to quantify the effect of tertiles of FGF-23 on the odds of cognitive risk; models were adjusted for the same covariates as listed. All analyses were performed using Stata 10/MP (StataCorp LP).

**RESULTS**

**Cohort Characteristics**

Characteristics of the 702 participants, overall and by tertile of plasma FGF-23, are summarized in Table 1. Median
Kidney Medicine

Volume 2 | Issue 4 | July/August 2020

Table 2. Neurocognitive Test Scores in CKD Cohort

| Measure                        | Mean   | SD    | Confidence Interval (5th-95th percentile) | Cognitive Risk Threshold | N    | Percent at Risk |
|--------------------------------|--------|-------|------------------------------------------|--------------------------|------|-----------------|
| Intellectual Functioning       |        |       |                                          |                          |      |                 |
| WASI-2 IQ                     | 97.2   | 15.7  | 71-122                                   | ≤65                      | 590  | 23%             |
| Academic Achievement           |        |       |                                          |                          |      |                 |
| WIAT II-A Total Achievement    | 95.6   | 18.1  | 65-126                                   | ≤65                      | 289  | 29%             |
| Attention Regulation           |        |       |                                          |                          |      |                 |
| CPT-II Omission               | 52.8   | 14.4  | 42-81                                    | ≥60                      | 537  | 18%             |
| CPT-II Commission             | 51.6   | 11.0  | 33-66                                    | ≥60                      | 538  | 26%             |
| CPT-II VAR                    | 51.1   | 11.2  | 35-69                                    | ≥60                      | 538  | 25%             |
| CPT-II HIT REACT              | 49.0   | 12.0  | 32-73                                    | ≥60                      | 538  | 17%             |
| CPT-II DETECT                 | 52.0   | 10.3  | 33-65                                    | ≥60                      | 538  | 23%             |
| Executive Functioning          |        |       |                                          |                          |      |                 |
| Digit Span Backward           | 9.2    | 2.9   | 4-13                                     | ≤7                       | 269  | 27%             |
| BRIEF-P BRI                   | 52.9   | 11.7  | 38-76                                    | ≥60                      | 585  | 26%             |
| MI                            | 55.0   | 11.6  | 38-76                                    | ≥60                      | 582  | 32%             |
| GEC                           | 54.4   | 11.7  | 38-76                                    | ≥60                      | 662  | 31%             |

Note: Cognitive risk is defined as scores ≥1 SD below expected performance for age. Mean and SD of normative values for cognitive test scores provided the basis for establishing a risk category. IQ calculated from WASI-II: mean ± SD, 100 ± 15 (higher scores are better), ACHIEVE: achievement total scaled score derived from Word Reading, Numerical Operations, and Spelling from WIAT-II-A: mean ± SD, 100 ± 15 (higher scores are better), CPT-II scores depending on age: COMMISSION, HIT REACT, OMISSION, VAR, DETECT: mean ± SD, 50 ± 10 (higher scores are worse), Digits Span Backwards is a subset of Digits Span from the age-appropriate Wechsler Intelligence Scale for Children-IV Test: mean ± SD, 19 ± 3, higher scores are better. BRIEF-P all scores: BRI, MI, and GEC: mean ± SD, 50 ± 10 (higher scores are worse for BRI, MI, and GEC).

Abbreviations: BRI, Behavior Regulation Index scaled score from BRIEF; BRIEF-P, Behavior Rating Inventory of Executive Functions, parents rating; CKiD, Chronic Kidney Disease in Children; COMMISSION, Commission T Score; CPT-II, Conners’ Continuous Performance Test-II; DETECT, Detectability; GEC, Global Executive Composite scaled score from BRIEF derived from BRI and MI; HIT REACT, Hit Reaction time; IQ, intelligence quotient; MI, Metacognition Index scaled score from BRIEF; OMISSION, Omission T Score; SD, standard deviation; VAR, Variability; WASI-2, Wechsler Abbreviated Scales of Intelligence-2; WIAT-II-A, Wechsler Individual Achievement Test-II.

We then determined the percentage of children with CKD who were at cognitive risk (Table 2). When analyzed as a group, cognitive test scores in children with CKD were within the normal range. However, when individual patients were examined, a large percentage (18%-33%) of children were categorized as being at risk for cognitive dysfunction (ie, ≥1 SD below the test mean) for a given cognitive test. Specifically, the percentage of children at cognitive risk was 23% for IQ, 29% for total achievement, 18% to 26% for attention regulation, and 26 to 33% on parent ratings of executive functioning. Compared with the distribution in otherwise healthy children (ie, ~16%), these data demonstrate that a greater percentage than expected of children with mild to moderate CKD are at risk for cognitive dysfunction.

Associations of FGF-23 Concentrations With Cognitive Test Scores

Unadjusted associations between plasma FGF-23 levels and cognitive test scores are shown in Table S2. Among the cognitive domains examined, scores for the following tests showed associations (P < 0.1) by either FGF-23 tertile, log2FGF-23, or both: CPT-II tests for Errors of Omissions, a measure of selective attention; Variability and Hit Reaction Time, measures of attention regulation; Detectability, a measure of overall attention; and WIAT II-A Total Achievement score.

Measures of Cognitive Function and Cognitive Risk Assessment

As a group, children with CKD performed near the expected cognitive score for their age (Table 2). WASI-2 IQ score (mean ± SD, 97.2 ± 15.6) was in the normal range. WIAT-II-A Total Achievement score (mean ± SD, 95.6 ± 18.1) also was within the normal range. Mean values for measures of attention regulation (ie, CPT-II Errors of Omission, Errors of Commission, Hit Reaction Time, Detectability, and Variability) were age appropriate. Parental ratings of executive functions revealed few overall problems, with the 3 major BRIEF indexes (BRI, Metacognition Index, and Global Executive Composite) reflecting age-appropriate functioning.

age was 12 years, 38% were female, 68% were white, and 15% were African American, with 14% reporting Hispanic ethnicity. Median eGFR was 54.2 (interquartile range, 40-68) mL/min/1.73 m2. CKD was caused by nonglomerular disease in 68% of participants, 65% reported taking anti-hypertensive medications, 27% took active vitamin D sterols, and 17% took phosphate binders. Median plasma FGF-23 concentration was 111 (interquartile range, 78-147.5) RU/mL. Compared with the lowest FGF-23 tertile (≤87.5 RU/mL), participants in the highest tertile (≥147.5 RU/mL) had lower eGFRs and were more likely to have hypertension medications, 27% took active vitamin D sterols, and 17% took phosphate binders. Median plasma FGF-23 concentration was 111 (interquartile range, 78-147.5) RU/mL. Compared with the lowest FGF-23 tertile (≤87.5 RU/mL), participants in the highest tertile (≥147.5 RU/mL) had lower eGFRs and were more likely to have
Multivariable Regression Analysis of Associations of FGF-23 With Cognitive Function

The association between log₂ FGF-23 and FGF-23 tertile for cognitive test scores showing an unadjusted association \( (P < 0.1) \) with FGF-23 level was further examined using multivariable linear regression; the fully adjusted model included age, sex, race, eGFR, UPCR, and systolic hypertension (Tables 3, S2, and S3). We observed that log₂ FGF-23 level remained significantly associated with poorer scores for the 5 measures of attention regulation, specifically CPT-II Errors of Omission, Variability, and Hit Reaction Time in the fully adjusted model (Table 3). Interestingly, the strength of the association between plasma FGF-23 level and CPT-II Errors of Omission, Variability, and Hit Reaction Time in the fully adjusted model (Table 3). Among the covariates, younger age was associated with lower performance for CPT-II Errors of Omission, Variability, and Hit Reaction Time and non-white race was associated with poorer performance for CPT-II Errors of Omission. CPT-II Detectability, CPT-II Errors of Commission, and WIAT II-A scores were not associated with FGF-23 levels in fully adjusted analyses. The associations between plasma FGF-23 levels and test scores for CPT-II Errors of Omission, Variability, and Hit Reaction Time were also significant in the fully adjusted model when plasma FGF-23 level was expressed as tertiles (Table 3).

Relationship Between FGF-23 Concentrations and Cognitive Risk

The prevalence of cognitive risk for each cognitive test according to FGF-23 tertiles is shown in Table 4. In the unadjusted analysis, cognitive risk showed associations \( (P < 0.1) \) either by FGF-23 tertile or log₂ FGF-23 or both with the following tests: WASI-2 IQ, CPT-II Errors of Omission and Hit Reaction Time, and the BRIEF BRI summary score. In the fully adjusted model, higher FGF-23 tertile was significantly associated with increased cognitive risk for 2 of the 5 measures of attention regulation (CPT-II Errors of Omission and Hit Reaction Time; Tables 4 and S4). Compared with children with FGF-23 levels ≤ 87.5 RU/mL, children with FGF-23 levels ≥ 147.5 RU/mL had 9% (26% vs 17%) and 6% (22% vs 16%) higher rates of cognitive risk on CPT-II Errors of Omission and Hit Reaction Time, respectively. In pairwise comparisons for these 2 cognitive measures, there is a statistically significant difference between tertiles 2 and 3 \( (P < 0.01) \) but not between tertiles 1 and 2. WASI-2 IQ, a measure of intellectual functioning, and summary scores from the BRIEF test, measures of executive function, were not associated with FGF-23 levels in fully adjusted analyses. The associations between plasma FGF-23 levels and cognitive risk for CPT-II Errors of Omission were also significant in the fully adjusted model when expressed as FGF-23 level doubling (Table 4).

Relationship Between Mineral Metabolites and Cognitive Function

To assess the specificity of the association of FGF-23 levels with cognitive dysfunction, we examined whether levels of other markers of mineral metabolism were associated with differences in cognitive test performance in children with CKD. In the fully adjusted analyses, 25(OH)D, 1,25(OH)₂D, PTH, calcium, and phosphorus z scores did not associate with any of the cognitive test scores listed in Table 2. There was a trend toward significance for associations between phosphorus z scores and CPT-II Errors of Omission \( (P = 0.08) \) and between serum 25(OH)D levels and CPT-II Errors of Commission \( (P = 0.06) \) in the fully adjusted analyses.

DISCUSSION

In the present cohort of 702 children with predialysis CKD, higher plasma FGF-23 levels were independently
associated with poor performance in 3 of the 5 cognitive tests for selective attention and attention regulation. Risk for poor performance (defined as ≥1 SD below test mean) on CPT-II Errors of Omission was 1.5 times greater in participants with FGF-23 levels ≥ 147.5 RU/mL compared with those with FGF-23 levels ≤ 87.5 RU/mL. We also observed a significant association between log₂>FGF-23 and FGF-23 tertiles with other measures of attention, specifically CPT-II Hit Reaction Time and Variability, but not for CPT-II Errors of Commission and Detectability. The associations remained significant after adjustment for known risk factors for cognitive dysfunction, including eGFR, systolic BP, and proteinuria. More importantly, these associations were specific for FGF-23 levels because no association was found for levels of other markers of CKD—mineral and bone disorders, including vitamin D metabolites, PTH, calcium, and phosphorus.

In a child with CKD, cognitive deficits can have a major adverse effect over their lifetime on educational achievement, disease self-management, occupational outcome, and health-related quality of life. The substantial improvements in the care of CKD realized over the last 4 decades are predicted to be neuroprotective. However, emerging studies show that some children with CKD remain at risk for cognitive dysfunction. The present study provides the first large-scale evaluation of associations between CKD—mineral and bone disorders and cognitive function. As a group, children with mild to moderate CKD in our study tested within age-appropriate norms for IQ, academic achievement, and attention/executive functions. However, when individual patients were examined, a substantial proportion of children were at risk for cognitive dysfunction; the prevalence of risk ranged from ~18% to 33% for any given cognitive test. These findings were consistent with prior reports.

In our prior study, we observed that GFR and proteinuria were associated with poor performance on some but not all of the neurocognitive tests examined. Specifically, iothalamate-based GFR was a significant predictor of academic achievement skills, with each 10 mL/min/1.73 m² increase in iothalamate GFR being associated with a 1.4-point increase in achievement skills, but not with any of the other cognitive tests examined. Proteinuria was a significant predictor for poor performance on Verbal IQ and Full-Scale IQ, but not for Performance IQ, and for poor performance on CPT-II Errors of Omission, but not for Errors of Commission. These findings suggest that there may be a particular threshold for kidney disease burden before one can observe cognitive dysfunction in a specific domain, and the adverse effects of early CKD on cognition can only be delineated with more precise measurements of the respective cognitive domains (intelligence, achievement, attention dimension, and executive functions).

Table 4. Adjusted Associations Between FGF-23 Levels and Cognitive Risk for Attention Regulation

| Cognitive Function Tests | Association With log₂>FGF-23 Tertile 2 vs 1 | Association With FGF-23 Tertile 3 vs 1 |
|--------------------------|---------------------------------------------|---------------------------------------------|
|                          | Coefficient (β) (95% CI) | P            | Coefficient (β) (95% CI) | P            |
| CPT-II Omissions        | 0.4 (0.1 to 0.6)      | 0.002*       | −0.06 (−0.2 to 0.8) | 0.8          |
| CPT-II Commissions      | −0.09 (−0.3 to −0.1) | 0.5          | 0.03 (−0.5 to 0.5) | 0.9          |
| CPT-II HIT REACT        | 0.2 (−0.03 to 0.4)   | 0.08         | −0.2 (−0.7 to 0.3) | 0.4          |
| CPT-II DETECT           | 0.2 (−0.07 to 0.4)   | 0.2          | 0.03 (−0.6 to 0.6) | 0.9          |
|                          | 0.1 (−0.08 to 0.4)   | 0.2          | 0.2 (−0.4 to 0.7) | 0.7          |

Note: Plasma FGF-23 concentrations were either log base 2 transformed (representing doubling of FGF-23) or expressed as tertiles (β coefficient and P for highest vs lowest tertile). Outcome of interest is cognitive risk defined as a score > 1 standard deviation below age-specific mean on the CPT-II scores depending on age: OMISSION, COMMISSION, VAR, HIT REACT, and DETECT. Coefficient represents β value of FGF-23 effect after accounting for all other variables in the model. Covariates: age, sex, race, Hispanic, estimated glomerular filtration rate, urine protein-creatinine ratio ≥ 2, and hypertension (95th percentile systolic blood pressure). N = 490 for CPT-II Omissions, N = 491 for CPT-II Commissions, VAR, HIT REACT and DETECT. Abbreviations: CI, confidence interval of z score; COMMISSION, Commission T Score; CPT-II, Conners’ Continuous Performance Test-II; DETECT, Detectability; FGF-23, fibroblast growth factor 23; HIT REACT, Hit Reaction time; OMISSION, Omission T Score; VAR, Variability.

*Statistically significant.
Moreover, unlike FGF-23, elevated BP was not associated with CPT-II cognitive tests in the CKiD cohort.

Observations from CKiD were corroborated in a recent meta-analysis that assessed cognitive and educational outcomes in children with CKD.⁴⁰ In that analysis, cognitive deficits were more prevalent than in the general population; the specific patterns of deficit were evident for attention, memory, and executive function domains. Regarding attention regulation, children with CKD showed problems with attention regulation when assessed using CPT-II Errors of Omission and Commission tests.⁴⁰ In the present study, we found that level of FGF-23, a marker of disordered bone and mineral metabolism, is a strong independent predictor of poor attention regulation, with plasma FGF-23 levels ≥ 147.5 RU/mL associated with 50% greater risk for poor attention regulation in children with mild to moderate CKD.

To our knowledge, to date our study is the first to examine the associations between FGF-23 levels and cognitive function using a targeted array of neurocognitive tests in a large representative cohort of children with CKD. In adults with CKD, whether FGF-23 level associates with cognitive function is unclear.²⁶-²⁸ Further, risk factors for cognitive dysfunction in children may be distinctly different from those in adults, thus limiting comparisons. In 2 studies of adult patients with and without CKD, no association between FGF-23 level and incident cognitive dysfunction was observed.²⁶,²⁸ However, cognitive testing was limited to telephone interviews, and direct assessment of cognitive function was not performed. In contrast, in a smaller cohort of adults receiving dialysis, high plasma FGF-23 concentrations associated with memory deficits when individuals were assessed using a detailed battery of neurocognitive tests.²⁷ In our study, we found statistically significant relationships between higher FGF-23 levels and poor selective attention and attention regulation more generally—functions that can be strongly associated with working memory and short-term recall.

Whether FGF-23 contributes directly or indirectly to biological mechanisms underlying impaired cognitive function in children with CKD remains to be determined. There is a paucity of literature on the actions of FGF-23 in the central nervous system. FGF-23 has been detected in cerebrospinal fluid in humans and in rodent brain.²⁵,²⁹,⁴¹ In vitro cultures of murine hippocampal cells demonstrate that FGF-23 modulates neuron morphology and synaptic density,²⁵ potentially making such functions as attention and memory vulnerable to FGF-23 excess. However, the biological effect of such regulation of hippocampal neural networks by FGF-23 is yet to be investigated. Of interest, the role of the hippocampus in attention regulation was recently investigated; magnetic resonance imaging performed in a large cohort of children with attention deficit-hyperactivity disorder showed reduced brain volumes in the amygdala, hippocampus, and other areas known to control attention-related behavior.⁴² The present study demonstrated that high FGF-23 concentrations in children with CKD associate with poor attention regulation, findings that support the hypothesis that FGF-23 has an important biological role in the central nervous system.

Our study has some limitations. First, we did not measure serum klotho in our cohort. Klotho is a cofactor for renal actions of FGF-23 to inhibit phosphate transport and 1,25(OH)₂D synthesis.⁴³ Higher soluble klotho concentrations were recently shown to associate with better cognitive function in preclinical studies and in the aging population.⁴⁴ Currently, reliable assays to measure klotho in children with CKD are not available and normal reference ranges in children are not well established. Second, further studies are needed to determine whether FGF-23 level associates with cognitive dysfunction in CKD in other population cohorts and to assess the effects of cumulative FGF-23 excess on cognitive function over time. Should our findings be replicated in both cross-sectional and longitudinal investigations, this would suggest that higher FGF-23 level is a biological marker for cognitive dysfunction in children.

**SUPPLEMENTARY MATERIAL**

**Supplementary File (PDF)**

**Table S1:** List of cognitive function tests

**Table S2:** Neurocognitive test scores by FGF-23 tertiles and unadjusted association with log₂FGF-23

**Table S3:** Neurocognitive test scores and adjusted associations between FGF-23 and cognitive tests for attention regulation, all models

**Table S4:** Proportion of children at cognitive risk according to FGF-23 tertile and unadjusted association with log₂FGF-23

**Table S5:** Adjusted associations between FGF-23 and cognitive risk for attention regulation, all models

**ARTICLE INFORMATION**

**Authors’ Full Names and Academic Degrees:** Jennifer S. Yokoyama, PhD, Mina Matsuda-Abedini, MD, Michelle R. Denburg, MD, Juhi Kumar, MD, Bradley A. Warady, MD, Susan L. Furth, MD, Stephen R. Hooper, PhD, Anthony A. Portale, MD, and Farzana Perwad, MD.

**Authors’ Affiliations:** Department of Neurology, Memory and Aging Center (JSY), and Department of Radiology and Biomedical Imaging (JSY), University of California, San Francisco, San Francisco, CA; Division of Nephrology, University of Toronto, The Hospital for Sick Children, Toronto, ON, Canada (MM-A); Children’s Hospital of Philadelphia, Division of Nephrology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA (MRD, SLF); Division of Nephrology, Weill Cornell Medical College, New York, NY (UK); Division of Nephrology, Children’s Mercy Kansas City, Kansas City, MO (BAW); Department of Allied Health Sciences, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC (SRH); and Division of Nephrology, Department of Pediatrics, University of California, San Francisco, San Francisco, CA (AAP, FP).

**Address for Correspondence:** Farzana Perwad, MD, University of California, San Francisco, 550 16th St, San Francisco, CA 94158. E-mail: farzana.perwad@ucsf.edu

**Authors’ Contributions:** Study design: FP, AAP, MM-A; data analysis/interpretation: JSY, FP; data collection: MD, JK, BAW,
SLF, SRH; supervision/mentorship: BAW, SLF. Each author contributed important intellectual content during manuscript drafting or revision and accepts accountability for the overall work by ensuring that questions pertaining to the accuracy or integrity of any portion of the work are appropriately investigated and resolved.

Support: Primary support for data analysis was provided by the National Institutes of Health/National Institute of Aging K01 AG049152 (Dr Yokoyama), Larry L. Hillbom Foundation 2016-A-005-SUP (Dr Yokoyama), Tau Consortium (Dr Yokoyama), Bluefield Project to Cure FTD (Dr Yokoyama), and John Douglas French Alzheimer’s Foundation (Dr Yokoyama). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Financial Disclosure: The authors declare that they have no relevant financial interests.

Acknowledgements: We thank all participants for contributions to this research. Data in this manuscript were collected by the CKiD prospective cohort study with clinical coordinating centers (Principal Investigators) at Children’s Mercy Hospital and the University of Missouri–Kansas City (Bradley A. Warady, MD) and Children’s Hospital of Philadelphia (Susan L. Furth, MD, PhD), Central Biochemistry Laboratory (George Schwartz, MD) at the University of Rochester Medical Center, and data coordinating center (Alvaro Muñoz, PhD) at the Johns Hopkins Bloomberg School of Public Health. CKiD is funded by the National Institute of Diabetes and Digestive and Kidney Diseases, with additional funding from the National Institute of Child Health and Human Development and the National Heart, Lung, and Blood Institute (U01-DK-66143, U01-DK-66174, U01DK-082194, U01-DK-66116). The CKiD website is located at http://www.statepi.jhsph.edu/ckid.

Peer Review: Received October 22, 2019. Evaluated by 1 external peer reviewer, with direct editorial input from the Statistical Editor, an Associate Editor, and the Editor-in-Chief. Accepted in revised form March 16, 2020.

REFERENCES

1. McDonald SP, Craig JC. Long-term survival of children with end-stage renal disease. N Engl J Med. 2004;350:2654-2662.
2. Saran R, Li Y, Robinson B, et al. US Renal Data System 2014 Annual Data Report: epidemiology of kidney disease in the United States. J Am Soc Nephrol. 2015;66:Svi, S1-Svi, 305.
3. Furth SL, Hwang W, Yang C, Neu AM, Fivush BA, Powe NR. Growth failure, risk of hospitalization and death for children with end-stage renal disease. Pediatr Nephrol. 2002;17:450-455.
4. Gipson DS, Hooper SR, Duquette PJ, et al. Memory and executive functions in pediatric chronic kidney disease. Child Neuropsychol. 2006;12:391-405.
5. Gerson AC, Butler R, Moxey-Mims M, et al. Neurocognitive outcomes in children with chronic kidney disease: current findings and contemporary endeavors. Ment Retard Dev Disabil Res Rev. 2006;12:208-215.
6. Harshman LA, Johnson RJ, Matheson MB, et al. Academic achievement in children with chronic kidney disease: a report from the CKiD cohort. Pediatr Nephrol. 2019;34:689-696.
7. Hooper SR, Gerson AC, Butler RW, et al. Neurocognitive functioning of children and adolescents with mild-to-moderate chronic kidney disease. Clin J Am Soc Nephrol. 2011;6:1824-1830.
8. Bartosh SM, Levenson G, Robillard D, Sollinger HW. Long-term outcomes in pediatric renal transplant recipients who survive into adulthood. Transplantation. 2003;76:1195-1200.
9. Groothoff JW, Grootenhuis M, Dommerholt A, Gruppen MP, Offringa M, Heymans HS. Impaired cognition and schooling in adults with end stage renal disease since childhood. Arch Dis Child. 2002;87:380-385.
10. Kalirao P, Pederson S, Foley RN, et al. Cognitive impairment in peritoneal dialysis patients. J Am Soc Nephrol. 2011;57:612-620.
11. Shimada T, Mizutani S, Muto T, et al. Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proc Natl Acad Sci U S A. 2001;98:6500-6505.
12. Shimada T, Hasegawa H, Yamazaki Y, et al. FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res. 2004;19:429-435.
13. Perwad F, Zhang MY, Tenenhouse HS, Portale AA. Fibroblast growth factor 23 impairs phosphorus and vitamin D metabolism in vivo and suppresses 25-hydroxyvitamin D-1alpha-hydroxylase expression in vitro. Am J Physiol Renal Physiol. 2007;293:F1577-F1583.
14. Isakova T, Wahl P, Vargas GS, et al. Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Kidney Int. 2011;79:1370-1378.
15. Portale AA, Wolf M, Juppirn H, et al. Disordered FGF23 and mineral metabolism in children with CKD. Clin J Am Soc Nephrol. 2014;9:344-353.
16. Fliser D, Kollerits B, Neyer U, et al. Fibroblast growth factor 23 (FGF23) predicts progression of chronic kidney disease: the Mild to Moderate Kidney Disease (MMKD) Study. J Am Soc Nephrol. 2007;18:2600-2608.
17. Sciaila JJ, Astor BC, Isakova T, Xie H, Appel LJ, Wolf M. Mineral metabolites and CKD progression in African Americans. J Am Soc Nephrol. 2013;24:125-135.
18. Portale AA, Wolf MS, Messinger S, et al. Fibroblast growth factor 23 and risk of CKD progression in children. Clin J Am Soc Nephrol. 2016;11:1989-1998.
19. Mitsnepes MM, Betoko A, Schneider MF, et al. FGF23 and left ventricular hypertrophy in children with chronic kidney disease. Clin J Am Soc Nephrol. 2018;13:45-52.
20. Faul C, Amaral AP, Oskouei B, et al. FGF23 induces left ventricular hypertrophy. J Clin Invest. 2011;121:4399-4408.
21. Isakova T, Xie H, Yang W, et al. Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease. JAMA. 2011;305:2432-2439.
22. Gutierrez OM, Mannstadt M, Isakova T, et al. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med. 2008;359:584-592.
23. Parker BD, Schurgers LJ, Brandenburg VM, et al. The associations of fibroblast growth factor 23 and uncarboxylated matrix Glα protein with mortality in coronary artery disease: the Heart and Soul Study. Ann Intern Med. 2010;152:640-648.
24. Sciaila JJ, Xie H, Rahman M, et al. Fibroblast growth factor-23 and cardiovascular events in CKD. J Am Soc Nephrol. 2014;25:349-360.
25. Hensel N, Schon A, Koenen T, et al. Fibroblast growth factor 23 signaling in hippocampal cells: impact on neuronal morphology and synaptic density. J Neurochem. 2016;137:756-769.
26. Panwar B, Judd SE, Howard VJ, Jenny NS, Wadley VG, Gutierrez OM. Vitamin D, fibroblast growth factor 23 and incidental cognitive impairment: findings from the REGARDS Study. PLoS One. 2016;11:e0158571.
27. Drew DA, Tighiouart H, Scott TM, et al. FGF-23 and cognitive performance in hemodialysis patients. Hemodial Int. 2014;18:78-86.
28. Jovanovich AJ, Chonchol M, Brady CB, et al. 25-Vitamin D, 1,25-vitamin D, parathyroid hormone, fibroblast growth factor-23 and cognitive function in men with advanced CKD: a veteran population. Clin Nephrol. 2014;82:S1-S4.
29. Kunert SK, Hartmann H, Haffner D, Leifheit-Nestler M. Klotho and fibroblast growth factor 23 in cerebrospinal fluid in children. *J Bone Miner Metab*. 2017;35:215-226.

30. Furth SL, Cole SR, Moxey-Mims M, et al. Design and methods of the Chronic Kidney Disease in Children (CKiD) prospective cohort study. *Clin J Am Soc Nephrol*. 2006;1:1006-1015.

31. Lande MB, Mendley SR, Matheson MB, et al. Association of blood pressure variability and neurocognition in children with chronic kidney disease. *Pediatr Nephrol*. 2016;31:2137-2144.

32. Warady BA, Abraham AG, Schwartz GJ, et al. Predictors of rapid progression of glomerular and nonglomerular kidney disease in children and adolescents: the Chronic Kidney Disease in Children (CKiD) cohort. *Am J Kidney Dis*. 2015;65:878-888.

33. Lande MB, Gerson AC, Hooper SR, et al. Casual blood pressure and neurocognitive function in children with chronic kidney disease: a report of the children with chronic kidney disease cohort study. *Clin J Am Soc Nephrol*. 2011;6:1831-1837.

34. Schwartz GJ, Schneider MF, Maier PS, et al. Improved equations estimating GFR in children with chronic kidney disease using an immunonephelometric determination of cystatin C. *Kidney Int*. 2012;82:445-453.

35. Ng DK, Schwartz GJ, Warady BA, Furth SL, Munoz A. Relationships of measured iohexol GFR and estimated GFR with CKD-related biomarkers in children and adolescents. *Am J Kidney Dis*. 2017;70:397-405.

36. Lockitch G, Halstead AC, Wadsworth L, Quigley G, Reston L, Jacobson B. Age- and sex-specific pediatric reference intervals and correlations for zinc, copper, selenium, iron, vitamins A and E, and related proteins. *Clin Chem*. 1988;34:1625-1628.

37. Ruebner RL, Laney N, Kim JY, et al. Neurocognitive dysfunction in children, adolescents, and young adults with CKD. *J Am Soc Nephrol*. 2016;67:567-575.

38. Lande MB, Kupferman JC. Blood pressure and cognitive function in children and adolescents. *Hypertension*. 2019;73:532-540.

39. Adams HR, Szilagyi PG, Gebhardt L, Lande MB. Learning and attention problems among children with pediatric primary hypertension. *Pediatrics*. 2010;126:e1425-e1429.

40. Chen K, Didsbury M, van ZA, et al. Neurocognitive and educational outcomes in children and adolescents with CKD: a systematic review and meta-analysis. *Clin J Am Soc Nephrol*. 2018;13:387-397.

41. Yamashita T, Yoshioka M, Itoh N. Identification of a novel fibroblast growth factor, FGF-23, preferentially expressed in the ventrolateral thalamic nucleus of the brain. *Biochem Biophys Res Commun*. 2000;277:494-498.

42. Hoogman M, Bralten J, Hibar DP, et al. Subcortical brain volume differences in participants with attention deficit hyperactivity disorder in children and adults: a cross-sectional mega-analysis. *Lancet Psychiatry*. 2017;4:310-319.

43. Urakawa I, Yamazaki Y, Shimada T, et al. Klotho converts canonical FGF receptor into a specific receptor for FGF23. *Nature*. 2006;444:770-774.

44. Dubal DB, Yokoyama JS, Zhu L, et al. Life extension factor klotho enhances cognition. *Cell Rep*. 2014;7:1065-1076.